Clinical Approaches in High-Risk Patients with CLL/SLL
Mazyar Shadman, MD, MPH, describes his clinical approach to treating patients with high-risk CLL/SLL, including those with or without del(17p) or TP53 mutations.
EP: 1.Clinical Approaches in High-Risk Patients with CLL/SLL
EP: 2.SEQUOIA Arm D Study: Zanubrutinib plus Venetoclax in Treatment-Naive CLL/SLL with del(17p) and/or TP53 Mutations
EP: 3.Updates from the CAPTIVATE Study Evaluating Ibrutinib + Venetoclax in TN CLL/SLL
EP: 4.Future Implications of Combination Regimens and Treatment Duration in CLL/SLL
EP: 5.Examining Toxicity Management of BTK Inhibitors for CLL/SLL
EP: 6.Treatment Paradigms for Clinical Progression of CLL/SLL Beyond Initial Therapies
EP: 7.Perspectives on Indirect Comparisons of BTK Inhibitors for R/R CLL/SLL
EP: 8.Additional Data and Key Takeaways in CLL/SLL from EHA 2024
EP: 9.Future Outlooks in the Treatment of CLL/SLL
Video content above is prompted by the following questions:
- How would you describe your current clinical approach for high-risk patients with CLL/SLL, including those with or without del(17p) and/or TP53 mutations?
- What are the goals of therapy for patients in this setting?
- What are some challenges and unmet needs for patients with CLL/SLL?
One Arm of SEQUOIA Trial Shows 100% Response in High-Risk CLL/SLL
August 15th 2024Zanubrutinib with venetoclax led to an overall response rate of 100% when used for treating patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma with 17p deletions and/or TP53 mutations.
Read More
Real-World Findings on TLS Prevention and Management With Venetoclax in CLL
July 8th 2024Mark Geyer, MD, and Yannis K. Valtis, MD, delved into the background and findings from a study looking at clinical and laboratory tumor lysis syndrome in patients with CLL who were treated with venetoclax in the inpatient and outpatient settings.
Read More
